Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sickle cell symptoms cause patients to miss work

Vendetti N et al. Presentation at Foundation for Sickle Cell Disease Research Annual Meeting, June 2018.

Key clinical point: Sickle cell patients reported missing work or being affected by their symptoms while working.

Major finding: Three-quarters of patients reported missing work in the last year because of SCD symptoms. This group reported missing a mean 37 days yearly.

Study details: Single-site survey-based study of 186 adults with SCD.

Disclosures: Pfizer sponsored the study. Mr. Vendetti is employed by Pfizer and holds Pfizer stock. A study coauthor is a Pfizer consultant.

Read the article.

Citation:

Vendetti N et al. Presentation at Foundation for Sickle Cell Disease Research Annual Meeting, June 2018.

This Week's Must Reads

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0

Must Reads in Anemia

Fewer sickle cell crises with L-glutamine use, Niihara Y et al. N Engl J Med. 2018 Jul 19;379(3):226-35.

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Hydroxyurea tolerated well in sickle cell patients, Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.

Sickle cell symptoms cause patients to miss work, Vendetti N et al. Presentation at Foundation for Sickle Cell Disease Research Annual Meeting, June 2018.

FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)